Srini Ramanathan
Corporate Officer/Principal bei ROIVANT SCIENCES LTD.
Profil
Srini Ramanathan is currently the Chief Development Officer at Roivant Sciences Ltd.
Prior to this, he worked as the Senior VP-Research & Development Sciences at Horizon Therapeutics Plc.
He holds a doctorate degree from Rutgers State University of New Jersey and a graduate degree from Duquesne University School of Law.
Aktive Positionen von Srini Ramanathan
| Unternehmen | Position | Beginn |
|---|---|---|
| ROIVANT SCIENCES LTD. | Corporate Officer/Principal | 02.05.2022 |
Ehemalige bekannte Positionen von Srini Ramanathan
| Unternehmen | Position | Ende |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Ausbildung von Srini Ramanathan
| Rutgers State University of New Jersey | Doctorate Degree |
| Duquesne University School of Law | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ROIVANT SCIENCES LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
